Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Running, not enrolling · Phase 2

Conditions studied: Neoplasms

In brief

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.

Key facts

Study ID: NCT06703346
Run by: USWM CT, LLC
People needed: 87
Starts: 2019-12-31
Expected to finish: 2026-07-31
Last updated by the study team: 2026-04-08

Who can join

Age: 10 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Participant must be ≥10 years of age at the time of signing the informed consent.
Participant scheduled to receive clinical drug product supply must also weigh ≥40 kg.
Participant has a diagnosis of synovial sarcoma or myxoid/round cell liposarcoma, confirmed by local histopathology with evidence of disease-specific translocation.
Participant has advanced (metastatic or unresectable) synovial sarcoma or myxoid/round cell liposarcoma. Unresectable refers to a tumor lesion in which clear surgical excision margins cannot be obtained without leading to significant functional compromise.
Male or female. Contraception requirements will apply at the time of leukapharesis and treatment.
Life expectancy ≥24 weeks
Participant has confirmed evidence of a relevant disease-specific translocation per below:
For synovial sarcoma, presence of a translocation involving chromosome 18 (SYT gene) and/or chromosome X (SSX1, SSX2 or SSX4 genes).
For myxoid/round cell liposarcoma, presence of a translocation involving chromosome 12 (DDIT3 gene) and/or chromosome 16 (FUS gene) and/or chromosome 22 (EWSR1 gene).
Participant is either currently being treated with or has completed at least one standard-of-care treatment including anthracycline-containing regimens (e.g., doxorubicin alone, doxorubicin with ifosfamide) for advanced (metastatic or inoperable) disease. Participants who are intolerant to anthracycline may receive ifosfamide alone unless intolerant to or ineligible to receive ifosfamide. Participants who received anthracycline-based therapy in the neoadjuvant/adjuvant setting and progressed will be eligible.
Participant must be positive for HLA-A*02:01, HLA-A*02:05, and/or HLA-A*02:06 alleles by a validated test in a designated central lab prior to leukapheresis
Participant's tumor has been pathologically reviewed by a designated central laboratory with confirmed positive NY-ESO-1 expression defined as ≥30% of cells that are 2+ or 3+ by immunohistochemistry.
Left ventricular ejection fraction ≥45% with no evidence of clinically significant pericardial effusion.
Performance status: for participants <16 years of age, Lansky >60, or for participants ≥16 and <18 years of age, Karnofsky >60, or for participants ≥18 years of age, Eastern Cooperative Oncology Group (ECOG) of 0-1.
Participant must have adequate organ function and blood cell counts, within 7 days prior to the day of the leukapheresis procedure
Participant is fit for leukapheresis and has adequate venous access for the cell collection
Female participants of childbearing potential (FCBP) must have a negative urine or serum pregnancy test.
Participant has measurable disease according to RECIST v1.1.
Participant has documented radiographic evidence of disease progression from prior line of therapy.
A biopsy (excisional, incisional, or core) of non-target tumor tissue obtained within 28 days prior to initiating lymphodepleting chemotherapy is mandatory if clinically feasible. This biopsy will be used as baseline for biomarker analyses. If it is not feasible to obtain a fresh biopsy, an archival tumor tissue (FFPE block) taken preferably after completion of the participant's last line of therapy, preferably within 90 days prior to initiating lymphodepleting chemotherapy, may be accepted.
A haematologist has been consulted prior to lymphodepletion in participants who have had a serious/significant bleeding/thrombosis history.

You may not qualify if…

Central nervous system (CNS) metastases.
Any other prior malignancy that is not in complete remission.
Previous treatment with genetically engineered NY-ESO-1-specific T cells.
Previous NY-ESO-1 vaccine or NY-ESO-1 targeting antibody.
Prior gene therapy using an integrating vector
Previous allogeneic hematopoietic stem cell transplant
Clinically significant systemic illness (serious active infections or significant cardiac, pulmonary, hepatic, or other organ dysfunction, that in the judgment of the Investigator would compromise the participant's ability to tolerate protocol therapy or significantly increase the risk of complications) or prior or active demyelinating disease
Participant has received cytotoxic therapy within 3 weeks prior to lymphodepleting chemotherapy
Systemic corticosteroids or any other immunosuppressive therapy within 2 weeks prior to lymphodepleting chemotherapy.
Participant has received ≥50 Gy to a significant volume of the pelvis, long bones or spine, or a cumulative dose of radiation that, in the Investigator's opinion would predispose patients to prolonged cytopenia after lymphodepletion.
All of the participant's measurable lesions have been irradiated within 3 months prior to lymphodepletion. An irradiated measurable lesion with unequivocal progression following irradiation may be considered a target lesion regardless of time from last radiotherapy dose.
Participant has received an anti-cancer vaccine within 2 months in the absence of tumor response. The participant should be excluded if their disease is responding to an experimental vaccine given within 6 months.
Participant has received live vaccine within 4 weeks prior to lymphodepletion or intends to receive live vaccine during the 3-month period following administration of lete-cel.
Participant has received immune therapy (monoclonal antibody therapy, checkpoint inhibitors) within 4 weeks of lymphodepletion.
Participant had major surgery ≥28 days of first dose of study intervention

Where it is running

City of Hope National Medical Center — Duarte, California, United States
Stanford Hospital and Clinics — Stanford, California, United States
Sarah Cannon Research Institute — Denver, Colorado, United States
Mayo Clinic Jacksonville — Jacksonville, Florida, United States
University of Chicago — Chicago, Illinois, United States
University of Iowa College of Medicine — Iowa City, Iowa, United States
Dana Farber Cancer Institute — Boston, Massachusetts, United States
Massachusetts General Hospital — Boston, Massachusetts, United States
University of Michigan Medical Center — Ann Arbor, Michigan, United States
Minnesota Oncology Hematology — Minneapolis, Minnesota, United States
Mayo Clinic Rochester — Rochester, Minnesota, United States
Washington University — St Louis, Missouri, United States
Memorial Sloan Kettering cancer center — New York, New York, United States
Duke University Medical Center — Durham, North Carolina, United States
Ohio State University-Columbus — Columbus, Ohio, United States
Oregon Health and Science University — Portland, Oregon, United States
University of Pittsburgh, Hillman Cancer centre — Pittsburgh, Pennsylvania, United States
Sarah Cannon Research Institute — Nashville, Tennessee, United States
University Of Texas Southwestern Medical Center — Dallas, Texas, United States
University of Texas Southwestern Medical Center — Dallas, Texas, United States
University of Utah — Salt Lake City, Utah, United States
Virginia Commonwealth University — Richmond, Virginia, United States
Fred Hutchinson Cancer Research Center — Seattle, Washington, United States
Froedtert Hospital — Milwaukee, Wisconsin, United States
Princess Margaret Cancer Centre — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.